Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
---|---|---|---|---|---|---|
SC 13G/A | 2024-02-16 | Kumar Neil | BridgeBio Pharma, Inc. | 9,959,504 | 5.6% | EDGAR |
SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | BridgeBio Pharma, Inc. | 12,800,294 | 7.4% | EDGAR |
SC 13G/A | 2024-01-29 | BlackRock Inc. | BridgeBio Pharma, Inc. | 10,156,773 | 5.8% | EDGAR |
SC 13G/A | 2024-01-23 | STATE STREET CORP | BridgeBio Pharma, Inc. | - | 2.9% | EDGAR |
SC 13D/A | 2023-11-22 | VIKING GLOBAL INVESTORS LP | BridgeBio Pharma, Inc. | 25,120,991 | 15.7% | EDGAR |
SC 13D/A | 2023-07-20 | VIKING GLOBAL INVESTORS LP | BridgeBio Pharma, Inc. | 25,120,991 | 15.7% | EDGAR |
SC 13G/A | 2023-02-14 | Kumar Neil | BridgeBio Pharma, Inc. | 9,823,908 | 6.4% | EDGAR |
SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | BridgeBio Pharma, Inc. | 10,591,455 | 7.1% | EDGAR |
SC 13G | 2023-02-08 | STATE STREET CORP | BridgeBio Pharma, Inc. | - | 5.9% | EDGAR |
SC 13G/A | 2023-02-01 | BlackRock Inc. | BridgeBio Pharma, Inc. | 9,834,401 | 6.6% | EDGAR |
SC 13G/A | 2022-02-15 | PERCEPTIVE ADVISORS LLC | BridgeBio Pharma, Inc. | 7,128,755 | 4.8% | EDGAR |
SC 13G/A | 2022-02-14 | Kumar Neil | BridgeBio Pharma, Inc. | 9,003,211 | 6.0% | EDGAR |
SC 13G/A | 2022-02-09 | VANGUARD GROUP INC | BridgeBio Pharma, Inc. | 9,331,683 | 6.3% | EDGAR |
SC 13G/A | 2022-02-03 | BlackRock Inc. | BridgeBio Pharma, Inc. | 9,275,590 | 6.3% | EDGAR |
SC 13D/A | 2021-02-17 | KKR Genetic Disorder L.P. | BridgeBio Pharma, Inc. | 31,060,971 | 20.9% | EDGAR |
SC 13G/A | 2021-02-16 | AMERICAN INTERNATIONAL GROUP, INC. | BridgeBio Pharma, Inc. | 3,381,412 | 2.8% | EDGAR |
SC 13G/A | 2021-02-16 | PERCEPTIVE ADVISORS LLC | BridgeBio Pharma, Inc. | 6,706,268 | 5.5% | EDGAR |
SC 13G/A | 2021-02-16 | Kumar Neil | BridgeBio Pharma, Inc. | 8,330,597 | 6.7% | EDGAR |
SC 13G | 2021-02-10 | VANGUARD GROUP INC | BridgeBio Pharma, Inc. | 6,441,312 | 5.2% | EDGAR |
SC 13G | 2021-02-05 | BlackRock Inc. | BridgeBio Pharma, Inc. | 6,517,544 | 5.3% | EDGAR |